Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Brunelli

Showing results (351-360 of 409) with videos related to

Pageof 41
Sort By:
Virchows Archiv : an International Journal of Pathology|November 8, 2023
mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapyAnna Caliò, Stefano Marletta, Giulio Settanni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological FactorsSara Pilotto, Isabella Sperduti, Silvia Novello, et al.
Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Societa Italiana Di Ecografia Urologica E Nefrologica|December 28, 2022
AB0 blood groups and oncological and functional outcomes in bladder cancer patients treated with radical cystectomyAlessandro Tafuri, Andrea Panunzio, Antonio Soldano, et al.
Plos One|December 14, 2012
True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugsMatteo Brunelli, Emilio Bria, Alessia Nottegar, et al.
Pathologica|March 14, 2024
TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinomaMatteo Brunelli, Stefano Gobbo, Giorgio Malpeli, et al.
American Journal of Cancer Research|December 19, 2014
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitorsClaudia Fiorini, Francesco Massari, Serena Pedron, et al.
Cancer Genetics|February 19, 2017
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitorsMatteo Brunelli, Albino Eccher, Luca Cima, et al.
Indian Journal of Surgical Oncology|January 23, 2023
American Society of Anesthesiologists' (ASA) Physical Status System and Risk of Major Clavien-Dindo Complications After Robot-Assisted Radical Prostatectomy at Hospital Discharge: Analysis of 1143 Consecutive Prostate Cancer PatientsAntonio Benito Porcaro, Riccardo Rizzetto, Nelia Amigoni, et al.
Journal of Cancer Research and Clinical Oncology|July 30, 2013
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinomaEleonora Brunello, Giuseppe Bogina, Emilio Bria, et al.
Journal of Robotic Surgery|June 16, 2021
Severe intraoperative bleeding predicts the risk of perioperative blood transfusion after robot-assisted radical prostatectomyAntonio Benito Porcaro, Riccardo Rizzetto, Nelia Amigoni, et al.
Pageof 41

Showing results (351-360 of 409) with videos related to

Sort By:
Pageof 41
Virchows Archiv : an International Journal of Pathology|November 8, 2023
mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapyAnna Caliò, Stefano Marletta, Giulio Settanni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological FactorsSara Pilotto, Isabella Sperduti, Silvia Novello, et al.
Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Societa Italiana Di Ecografia Urologica E Nefrologica|December 28, 2022
AB0 blood groups and oncological and functional outcomes in bladder cancer patients treated with radical cystectomyAlessandro Tafuri, Andrea Panunzio, Antonio Soldano, et al.
Plos One|December 14, 2012
True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugsMatteo Brunelli, Emilio Bria, Alessia Nottegar, et al.
Pathologica|March 14, 2024
TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinomaMatteo Brunelli, Stefano Gobbo, Giorgio Malpeli, et al.
American Journal of Cancer Research|December 19, 2014
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitorsClaudia Fiorini, Francesco Massari, Serena Pedron, et al.
Cancer Genetics|February 19, 2017
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitorsMatteo Brunelli, Albino Eccher, Luca Cima, et al.
Indian Journal of Surgical Oncology|January 23, 2023
American Society of Anesthesiologists' (ASA) Physical Status System and Risk of Major Clavien-Dindo Complications After Robot-Assisted Radical Prostatectomy at Hospital Discharge: Analysis of 1143 Consecutive Prostate Cancer PatientsAntonio Benito Porcaro, Riccardo Rizzetto, Nelia Amigoni, et al.
Journal of Cancer Research and Clinical Oncology|July 30, 2013
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinomaEleonora Brunello, Giuseppe Bogina, Emilio Bria, et al.
Journal of Robotic Surgery|June 16, 2021
Severe intraoperative bleeding predicts the risk of perioperative blood transfusion after robot-assisted radical prostatectomyAntonio Benito Porcaro, Riccardo Rizzetto, Nelia Amigoni, et al.
Pageof 41